Ventana Financial Statements From 2010 to 2024
| VNTA Stock | USD 0.0004 0.00 0.00% |
Check Ventana Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ventana Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Ventana financial statements analysis is a perfect complement when working with Ventana Biotech Valuation or Volatility modules.
Ventana |
Ventana Biotech Company Current Valuation Analysis
Ventana Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ventana Biotech Current Valuation | 165.2 K |
Most of Ventana Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ventana Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ventana Biotech has a Current Valuation of 165.2 K. This is 100.0% lower than that of the Financial Services sector and significantly higher than that of the Shell Companies industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Ventana Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ventana Biotech's current stock value. Our valuation model uses many indicators to compare Ventana Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ventana Biotech competition to find correlations between indicators driving Ventana Biotech's intrinsic value. More Info.Ventana Biotech is rated below average in current valuation category among its peers. It is rated below average in shares outstanding category among its peers creating about 333.33 of Shares Outstanding per Current Valuation. Comparative valuation analysis is a catch-all model that can be used if you cannot value Ventana Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Ventana Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Ventana Biotech Financial Statements
Ventana Biotech stakeholders use historical fundamental indicators, such as Ventana Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ventana Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ventana Biotech's assets and liabilities are reflected in the revenues and expenses on Ventana Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ventana Biotech. Please read more on our technical analysis and fundamental analysis pages.
Ventana Biotech, Inc., a development stage biotech company, identifies, evaluates, acquires, develops, and partners commercialization of intellectual property in the area of drug candidates for personalized medicine. Ventana Biotech, Inc. was founded in 1989 and is based in Butschwil, Switzerland. Ventana Biotech is traded on OTC Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ventana Pink Sheet
Ventana Biotech financial ratios help investors to determine whether Ventana Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ventana with respect to the benefits of owning Ventana Biotech security.